Crinetics Pharmaceuticals (CRNX) Total Current Liabilities (2017 - 2026)

Crinetics Pharmaceuticals' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $71.1 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 24.04% year-over-year to $71.1 million in Q1 2026; TTM through Mar 2026 was $71.1 million, a 24.04% increase from a year earlier, with the FY2025 full-year figure at $85.1 million, up 42.54% from the prior year.
• Total Current Liabilities slipped to $71.1 million in Q1 2026 per CRNX's latest filing, from $85.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $85.1 million in Q4 2025 and bottomed at $20.3 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $51.8 million (2024), against an average of $48.1 million.
• Across the five-year window, Total Current Liabilities surged 119.1% in 2022 and grew 10.71% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $27.7 million in 2022, then jumped by 58.5% to $43.9 million in 2023, then soared by 35.82% to $59.7 million in 2024, then jumped by 42.54% to $85.1 million in 2025, then decreased by 16.44% to $71.1 million in 2026.
• Per Business Quant, the three latest CRNX Total Current Liabilities figures stand at $71.1 million (Q1 2026), $85.1 million (Q4 2025), and $74.2 million (Q3 2025).